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Background: CFTR gene mutations have worldwide differences in prevalence and data on Chilean patients is scarce.
Methods: We studied 36 of the most common CFTR mutations in Chilean patients from the CF National Program [Programa Nacional de Fibrosis
Quística (PNFQ)] of the Ministry of Health of Chile.
Results: Two hundred and eighty-nine patients were studied. Fourteen different mutations were identified with an overall allele detection rate of
42.0%. Mutations with frequencies greater than 1% were p.F508del (30.3% of alleles), p.R334W (3.3%), p.G542X (2.4%), c.3849+10Kb CNT
(1.7%), and p.R553X (1.2%). A north to south geographical gradient was observed in the overall rate of detection.
Conclusions: Southern European CFTR mutations predominate in the Chilean population, but a high percentage of alleles remain unknown.
Geographical heterogeneity could be explained in part by admixture. Complementary analyses are necessary to allow for effective genetic
counselling and improve cost-effectiveness of screening and diagnostic tests.
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Cystic fibrosis (CF) is caused by CFTR (cystic fibrosis
transmembrane conductance regulator) gene mutations. Al-
though more than 1700 different CFTR mutations have been
reported [1], about 20 mutations have individual worldwide
frequencies greater than 0.1%, and can thus be considered
“common mutations” [2,3]. These common mutations vary by
geographic and/or ethnic origin.
Latin American countries, including Chile, have a high
ethnic admixture. There are few and limited studies of CFTR
mutations in Chilean patients. These studies have investigated
from 5 to 20 different mutations in a total of 104 patients from
six centers in three Chilean cities (Santiago, Viña del Mar and
Valdivia) [4–6], and shown an average rate detection of 50.0%
with predominance of p.F508del (37.0%).d by Elsevier B.V. All rights reserved.
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mutation panel of 289 patients from the Cystic Fibrosis National
Program [Programa Nacional de Fibrosis Quística, (PNFQ)]. It
has been estimated that about 90% of CF patients are seen in the
Public Health System throughout the country (PNFQ target
population) [7], thus a study in this group of patients gives a
more complete view of the national mutation profile.
2. Methods
2.1. Participants
We studied patients from the CF National Program
[Programa Nacional de Fibrosis Quística (PNFQ)] of the
Ministry of Health of Chile recruited from March 2004 until
March of 2010. The Program incorporates patients with clinical
signs suggestive of CF plus established laboratory criteria [8].
At the time of this study, the PNFQ had 336 patients in its
database and all registered patients were invited to participate
through their treating physicians. Twenty-two patients have
been reported previously [6]. Local Ethics Committees
approved the study and informed consent was obtained from
all participating families.
For this analysis, three geographical areas were defined
according to Chilean administrative divisions or regions: a)
northern, from Arica to Coquimbo; b) central, from Valparaíso
to Maule, including Metropolitan Area of Santiago; and c)
southern, from Bío-Bío to Magallanes (Fig. 1).
2.2. Molecular analysis
A peripheral blood sample was collected from each patient.
CFTR mutations were determined by two methods throughout
the study period: “Cystic Fibrosis v3.0” (Celera Diagnostics,
Alameda, CA, USA), based on Oligonucleotide Ligation Assay
(OLA) technology, was used from 2004 to 2008, and “INNO-
LiPA CFTR19/CFTR17+Tn Update”, a multiparameter line
probe assay based on the reverse hybridization principle
(Innogenetics N. V., Gent, Belgium), was used since 2008.
The former detects 32 mutations while the latter provided
probes for the 36 most frequent CFTR-related mutations
worldwide. Mutations analyzed are listed in Table 1. All
molecular studies were performed at a single laboratory (Center
for Human Genetics, Facultad de Medicina Clínica Alemana-
Universidad del Desarrollo) in Santiago.
2.3. Data analysis
Analysis was carried out using Microsoft Excel 2007-based
data sheets (Microsoft Inc., Redmond, WA, USA), and SPSS
Statistics version 17.0 (SPSS Inc., Chicago, IL, USA).
3. Results
Three hundred and twenty four patients (96% of those
registered in PNFQ) participated in this study. Twenty-seven
families had more than one sibling with CF: twenty-one caseshad 2 affected siblings, five had 3, and one case had four
affected. All sibships showed concordant genotype and we
included only one case per each family for the statistical
analysis. This resulted in data from 578 alleles derived from 289
patients (130 female, 159 male). Thirty patients were from the
northern area (10.4%), 190 from the central area (65.7%), and
69 from the southern area (23.9%), which is in agreement with
the population distribution in Chile based on 2002 National
Census (north: 11.8%; center: 61.4%; and south: 26.8%) [9].
3.1. Mutation analysis
We found 14 different mutations in the 578 alleles analyzed
(Table 1), resulting in an overall detection rate of 42.0%. Seven
mutations had not been previously reported in the Chilean
population (p.1078delT, pG85E, c.3120+1 GNA, c.711+1 GNT,
p.R117H, p.A455E, and p.I148T).
The p.F508del mutation had the highest prevalence (30.6%).
In addition, another 4 mutations had a frequency greater than
1% (p.R334W, p.G542X, c.3849+10Kb CNT, and p.R553X),
encompassing 8.5% of the total alleles or 20.2% of detected
alleles, while 6 mutations were found in only one family.
In 78/289 patients (26.9%) two mutations were identified,
while in 120/289 (41.5%) patients, we failed to detect any
CFTR mutation. The remaining patients had only one mutation
detected. Forty-six patients were homozygotes, 44 (15.2%) for
p.F508del, and 2 (1.7%) for p.R334W. Thirty-one were
compound heterozygotes, 27 (9.3%) including one p.F508del
allele, and 4 (1.4%) for two other different mutations.
The allelic detection rate by geographical area (Fig. 1)
followed a decreasing north to south gradient, from 53.3% to
36.2%, respectively. Allelic frequencies in the central zone were
similar to the average countrywide results. In patients from the
northern regions, we found only four different mutations, while
in southern regions, seven different mutations were detected.
The p.F508del mutation was the most common in all three
areas, with 45.0% in the northern zone, 28.9% in the central
area, and 29.0% in the southern region. The p.R553X mutation
was found in all three zones but was over-represented in the
northern area (5.0% or 3/60 alleles), where it was the second
most common after p.F508del.
4. Discussion
This report summarizes the findings of the largest group of
CF patients examined in Chile and with the most comprehen-
sive mutation panel studied so far. Similarly to U.S. Hispanic
population and to Latin American countries, we found relatively
low detection rates compared to Europe and the US, and high
allelic heterogeneity.
Chilean ancestry evolved from an unequal admixture between
Amerindians with Asian origin [10,11] and Spanish conquerors.
Admixture occurred later and with lower frequency in the
southern zone, because of the prolonged Mapuche-Spaniard
conflict (i.e.“War of Arauco”, 1541–1883), which created a true
“internal frontier” dividing the country into two sides by the Bío-
Bío River, until the final part of the XIX century [12]. This fact
Fig. 1. Main mutations by geographical area.
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detection rates.
As in most countries, p.F508del was the most common
mutation detected in our patients, but in a lower proportion than
the average frequency of 45–46% published for Latin-
American countries [2,13], and the reported worldwidefrequency of 66% [2]. Several other prevalent mutations in
our Chilean cohort are common in Southern European countries
(i.e: p.R334W, p.G542X, and p.R1162X), and even more
prevalent in the Canary Islands (4%; 14.3%–25% and 6.1%,
respectively) [14,15], a point of halting for the Spanish
expeditions to America, including Columbus' first journey [16].
Table 1
CFTR mutation frequencies in Chilean patients compared to Latin-American and global data (n=number of alleles).
Mutation This study Rios et al. [4] Molina et al. [5] Repetto et al. [6] Perez et al. [13] CFGAC [2]
(n=578) (%) (n=72) (%) (n=36) (%) (n=100) (%) (n=4102) (%) (n=43,849) (%)
Chile Chile Chile Chile Latin-America a Worldwide
Unknown 58.0 66.6 61.1 34.0 36.7 22.7
p.F508del 30.6 29.2 30.6 45.0 47.1 66.0
p.R334W 3.1 – – 2.0 0.8 0.1
p.G542X 2.4 0 8.3 7.0 5.0 2.4
c.3849+10Kb CNT 1.7 – – 3.0 0.3 0.2
p.R553X 1.2 4.2 0 1.0 0.4 0.7
p.R1162X 0.9 – – 2.0 1.0 0.3
p.1078delT 0.5 – – 0 b0.1 0.1
p.G85E 0.5 – – – 0.8 0.2
p.W1282X 0.2 – – 5.0 1.0 1.2
c.3120+1 GNA 0.2 – – – 0.3 –
c.711+1 GNT 0.2 – – – 0.1 0.1
p.R117H 0.2 – – 0 b0.1 0.3
p.A455E 0.2 – – 0 0 0.1
p.I148T 0.2 – – – – –
p.G551D 0 0 0 1.0 0.1 1.6
p.N1303K 0 0 0 0 1.8 1.3
c.621+1 GNT 0 – – 0 0.2 0.7
c.1717-1 GNA 0 – – 0 0.3 0.6
p.I507del 0 – – 0 0.2 0.2
p.R347P 0 – – 0 0 0.2
c.2789+5 GNA 0 – – – 0.2 0.1
c.1898+1 GNA 0 – – – 0.1 0.1
c.2184delA 0 – – – b0.1 0.1
p.S549N 0 – 0 – 0.1 0.1
c.3659delC 0 – – 0 0.1 0.1
p.R560T 0 – – – 0 0.1
c.1811+1.6Kb ANG 0 – – – 0.4 –
c.2183AANG 0 – – 0 0.1 –
p.S549R 0 – – – 0.1 –
c.3272-26 ANG 0 – – – 0.1 –
c.3199del6 0 – – – b0.1 –
p.E60X 0 – – 0 0 –
c.3905insT 0 – – – 0 –
p.S1251N 0 – – 0 – –
CFTRdele2,3 0 – – – – –
p.R347H 0 – – – – –
p.V520F 0 – – – – –
p.Q552X 0 – – – – –
c.394delTT 0 – – – – –
c.711+1 GNA 0 – – – – –
c.2143delT 0 – – – – –
c.3876delA 0 – – – – –
a Data from Chilean patients published in Rios et al., Molina et al., and Repetto et al. [4–6] included in this publication were excluded in this table to avoid repetition.
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source of CF alleles detected in Chile. However, about half of
mutations remain uncharacterized, and though we cannot rule
out a European origin for them, they may stem from
Amerindians (Asian origin or novel private mutations). It is
also likely that some mutation(s) will be shared with other
countries in South America.
Direct gene sequencing [17,18] and search for CFTR
genomic rearrangements [19,20] are needed to detect other
possible regionally prevalent mutations and rare (private)
mutations not found with mutation-specific tests. This would
allow us to improve diagnostic confirmation, carrier analysisand genetic counselling, and assist in the future development of
a newborn screening program and cost-effective tests.Conflict of interest
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